Pacira BioSciences, Inc. (NASDAQ: PCRX) Stock Competitors & Peer Comparison
See PCRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PCRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PCRX | $36.38 | +0.11% | 1.5B | 13.99 | $2.60 | N/A |
| TAK | $20.08 | +2.40% | 63.9B | 14.44 | $1.39 | +3.52% |
| TEVA | $40.85 | -1.11% | 47.6B | 13.95 | $2.93 | N/A |
| HLN | $10.17 | +0.30% | 44.7B | 20.82 | $0.49 | +1.95% |
| ZTS | $80.04 | +0.57% | 33.1B | 12.17 | $6.58 | +2.62% |
| VTRS | $18.65 | +2.14% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.70 | -3.36% | 11.3B | 21.42 | $1.06 | N/A |
| RDY | $13.26 | +1.38% | 11B | 28.23 | $0.47 | +0.63% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
PCRX vs TAK Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TAK has a market cap of 63.9B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TAK trades at $20.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TAK's P/E ratio is 14.44. In terms of profitability, PCRX's ROE is +0.02%, compared to TAK's ROE of +0.02%. Regarding short-term risk, PCRX is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
PCRX vs TEVA Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TEVA has a market cap of 47.6B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TEVA trades at $40.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TEVA's P/E ratio is 13.95. In terms of profitability, PCRX's ROE is +0.02%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, PCRX is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TEVA's competition here
Haleon plc (NYSE: HLN)
PCRX vs HLN Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, HLN has a market cap of 44.7B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while HLN trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas HLN's P/E ratio is 20.82. In terms of profitability, PCRX's ROE is +0.02%, compared to HLN's ROE of +0.10%. Regarding short-term risk, PCRX is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
PCRX vs ZTS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ZTS has a market cap of 33.1B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ZTS trades at $80.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ZTS's P/E ratio is 12.17. In terms of profitability, PCRX's ROE is +0.02%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, PCRX is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
PCRX vs VTRS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while VTRS trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas VTRS's P/E ratio is 7.40. In terms of profitability, PCRX's ROE is +0.02%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
PCRX vs ITCI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ITCI's P/E ratio is -180.64. In terms of profitability, PCRX's ROE is +0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, PCRX is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
PCRX vs CTLT Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CTLT's P/E ratio is -27.84. In terms of profitability, PCRX's ROE is +0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, PCRX is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
PCRX vs ELAN Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ELAN has a market cap of 11.3B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ELAN trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ELAN's P/E ratio is 21.42. In terms of profitability, PCRX's ROE is +0.02%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
PCRX vs RDY Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, RDY has a market cap of 11B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while RDY trades at $13.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas RDY's P/E ratio is 28.23. In terms of profitability, PCRX's ROE is +0.02%, compared to RDY's ROE of +0.09%. Regarding short-term risk, PCRX is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
PCRX vs ALKS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ALKS trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ALKS's P/E ratio is 46.43. In terms of profitability, PCRX's ROE is +0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, PCRX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
PCRX vs LNTH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while LNTH trades at $100.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas LNTH's P/E ratio is 16.87. In terms of profitability, PCRX's ROE is +0.02%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, PCRX is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
PCRX vs AMRX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AMRX has a market cap of 6.3B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AMRX trades at $19.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AMRX's P/E ratio is 22.04. In terms of profitability, PCRX's ROE is +0.02%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, PCRX is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
PCRX vs RGC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, RGC has a market cap of 5.2B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while RGC trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas RGC's P/E ratio is -1045.00. In terms of profitability, PCRX's ROE is +0.02%, compared to RGC's ROE of -1.61%. Regarding short-term risk, PCRX is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
PCRX vs INDV Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while INDV trades at $34.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas INDV's P/E ratio is 9.53. In terms of profitability, PCRX's ROE is +0.02%, compared to INDV's ROE of -2.16%. Regarding short-term risk, PCRX is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
PCRX vs HCM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while HCM trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas HCM's P/E ratio is 142.55. In terms of profitability, PCRX's ROE is +0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, PCRX is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
PCRX vs ALVOW Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, PCRX's ROE is +0.02%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, PCRX is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
PCRX vs SUPN Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SUPN trades at $41.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SUPN's P/E ratio is 13.47. In terms of profitability, PCRX's ROE is +0.02%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, PCRX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
PCRX vs BHC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while BHC trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas BHC's P/E ratio is 1.64. In terms of profitability, PCRX's ROE is +0.02%, compared to BHC's ROE of +0.89%. Regarding short-term risk, PCRX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
PCRX vs PRGO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while PRGO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas PRGO's P/E ratio is 6.47. In terms of profitability, PCRX's ROE is +0.02%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, PCRX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
PCRX vs DCPH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas DCPH's P/E ratio is -11.58. In terms of profitability, PCRX's ROE is +0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, PCRX is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
PCRX vs AVDL Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, PCRX's ROE is +0.02%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, PCRX is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
PCRX vs EMBCV Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas EMBCV's P/E ratio is N/A. In terms of profitability, PCRX's ROE is +0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, PCRX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
PCRX vs TRLV Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TRLV has a market cap of 1.8B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TRLV trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TRLV's P/E ratio is -4.38. In terms of profitability, PCRX's ROE is +0.02%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, PCRX is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TRLV's competition here
Alvotech (NASDAQ: ALVO)
PCRX vs ALVO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ALVO trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ALVO's P/E ratio is -8.68. In terms of profitability, PCRX's ROE is +0.02%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, PCRX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALVO's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
PCRX vs DVAX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas DVAX's P/E ratio is -41.89. In terms of profitability, PCRX's ROE is +0.02%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, PCRX is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
PCRX vs ANIP Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ANIP trades at $72.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ANIP's P/E ratio is 8.84. In terms of profitability, PCRX's ROE is +0.02%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, PCRX is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
PCRX vs TARO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TARO's P/E ratio is 30.05. In terms of profitability, PCRX's ROE is +0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, PCRX is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
PCRX vs PAHC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while PAHC trades at $38.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas PAHC's P/E ratio is 13.24. In terms of profitability, PCRX's ROE is +0.02%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, PCRX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PAHC's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
PCRX vs ETON Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ETON trades at $50.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ETON's P/E ratio is 132.08. In terms of profitability, PCRX's ROE is +0.02%, compared to ETON's ROE of +0.40%. Regarding short-term risk, PCRX is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
PCRX vs CRON Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CRON trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CRON's P/E ratio is 16.79. In terms of profitability, PCRX's ROE is +0.02%, compared to CRON's ROE of +0.06%. Regarding short-term risk, PCRX is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
PCRX vs AMPH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AMPH trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AMPH's P/E ratio is 8.85. In terms of profitability, PCRX's ROE is +0.02%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, PCRX is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
PCRX vs HROW Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while HROW trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas HROW's P/E ratio is -28.35. In terms of profitability, PCRX's ROE is +0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, PCRX is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
PCRX vs PETQ Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas PETQ's P/E ratio is 83.73. In terms of profitability, PCRX's ROE is +0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, PCRX is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
PCRX vs COLL Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, COLL has a market cap of 756.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while COLL trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas COLL's P/E ratio is 2.91. In terms of profitability, PCRX's ROE is +0.02%, compared to COLL's ROE of +0.16%. Regarding short-term risk, PCRX is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
PCRX vs IRWD Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, IRWD has a market cap of 599.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while IRWD trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas IRWD's P/E ratio is 4.65. In terms of profitability, PCRX's ROE is +0.02%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, PCRX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
PCRX vs BDSI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas BDSI's P/E ratio is 6.82. In terms of profitability, PCRX's ROE is +0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, PCRX is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
PCRX vs EVO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, EVO has a market cap of 525.7M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while EVO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas EVO's P/E ratio is -2.09. In terms of profitability, PCRX's ROE is +0.02%, compared to EVO's ROE of -0.27%. Regarding short-term risk, PCRX is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
PCRX vs AQST Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AQST has a market cap of 508.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AQST trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AQST's P/E ratio is -6.23. In terms of profitability, PCRX's ROE is +0.02%, compared to AQST's ROE of +2.44%. Regarding short-term risk, PCRX is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
PCRX vs EOLS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, EOLS has a market cap of 486.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while EOLS trades at $7.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas EOLS's P/E ratio is -23.34. In terms of profitability, PCRX's ROE is +0.02%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, PCRX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
PCRX vs KMDA Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, KMDA has a market cap of 452.9M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while KMDA trades at $7.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas KMDA's P/E ratio is 20.66. In terms of profitability, PCRX's ROE is +0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, PCRX is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
PCRX vs TKNO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TKNO has a market cap of 396.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TKNO trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TKNO's P/E ratio is -23.84. In terms of profitability, PCRX's ROE is +0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, PCRX is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
PCRX vs TLRY Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TLRY trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TLRY's P/E ratio is -2.16. In terms of profitability, PCRX's ROE is +0.02%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, PCRX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
PCRX vs EBS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, EBS has a market cap of 322.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while EBS trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas EBS's P/E ratio is 4.37. In terms of profitability, PCRX's ROE is +0.02%, compared to EBS's ROE of -0.36%. Regarding short-term risk, PCRX is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
PCRX vs CGC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CGC has a market cap of 304.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CGC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CGC's P/E ratio is -1.61. In terms of profitability, PCRX's ROE is +0.02%, compared to CGC's ROE of -0.33%. Regarding short-term risk, PCRX is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
PCRX vs ALIM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ALIM's P/E ratio is 5.28. In terms of profitability, PCRX's ROE is +0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, PCRX is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
PCRX vs LNDC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas LNDC's P/E ratio is -4.04. In terms of profitability, PCRX's ROE is +0.02%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, PCRX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
PCRX vs ACB Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ACB trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ACB's P/E ratio is -2.87. In terms of profitability, PCRX's ROE is +0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, PCRX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
PCRX vs LFCR Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, LFCR has a market cap of 241.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while LFCR trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas LFCR's P/E ratio is -5.02. In terms of profitability, PCRX's ROE is +0.02%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, PCRX is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
PCRX vs TYHT Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TYHT's P/E ratio is -1.61. In terms of profitability, PCRX's ROE is +0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, PCRX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
PCRX vs SIGA Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SIGA has a market cap of 226.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SIGA trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SIGA's P/E ratio is 11.67. In terms of profitability, PCRX's ROE is +0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, PCRX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
PCRX vs GLAS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, GLAS has a market cap of 182M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while GLAS trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas GLAS's P/E ratio is -4.15. In terms of profitability, PCRX's ROE is +0.02%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, PCRX is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
PCRX vs REPH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas REPH's P/E ratio is -8.04. In terms of profitability, PCRX's ROE is +0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, PCRX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
PCRX vs THTX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas THTX's P/E ratio is -28.83. In terms of profitability, PCRX's ROE is +0.02%, compared to THTX's ROE of +0.36%. Regarding short-term risk, PCRX is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
PCRX vs ASRT Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ASRT's P/E ratio is -7.10. In terms of profitability, PCRX's ROE is +0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, PCRX is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
PCRX vs DERM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, DERM has a market cap of 147.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while DERM trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas DERM's P/E ratio is -23.73. In terms of profitability, PCRX's ROE is +0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, PCRX is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
PCRX vs CRDL Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CRDL has a market cap of 138.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CRDL trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CRDL's P/E ratio is -4.58. In terms of profitability, PCRX's ROE is +0.02%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, PCRX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
PCRX vs OGI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, OGI has a market cap of 132.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while OGI trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas OGI's P/E ratio is 2.10. In terms of profitability, PCRX's ROE is +0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, PCRX is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
PCRX vs ORGO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ORGO trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ORGO's P/E ratio is 34.00. In terms of profitability, PCRX's ROE is +0.02%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, PCRX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ORGO's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
PCRX vs CPIX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CPIX trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CPIX's P/E ratio is -19.90. In terms of profitability, PCRX's ROE is +0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, PCRX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
PCRX vs SCTL Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SCTL's P/E ratio is -7.86. In terms of profitability, PCRX's ROE is +0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, PCRX is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
PCRX vs BGM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, BGM has a market cap of 108.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while BGM trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas BGM's P/E ratio is -1.78. In terms of profitability, PCRX's ROE is +0.02%, compared to BGM's ROE of -0.05%. Regarding short-term risk, PCRX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
PCRX vs PROC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas PROC's P/E ratio is 1.53. In terms of profitability, PCRX's ROE is +0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, PCRX is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
PCRX vs OPTN Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas OPTN's P/E ratio is -4.42. In terms of profitability, PCRX's ROE is +0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, PCRX is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
PCRX vs ZOM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ZOM's P/E ratio is -1.62. In terms of profitability, PCRX's ROE is +0.02%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, PCRX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
PCRX vs GRVI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas GRVI's P/E ratio is 26.05. In terms of profitability, PCRX's ROE is +0.02%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, PCRX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
PCRX vs ZYBT Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ZYBT trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, PCRX's ROE is +0.02%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, PCRX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
PCRX vs ZYNE Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, PCRX's ROE is +0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, PCRX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
PCRX vs SSIC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SSIC's P/E ratio is 11.93. In terms of profitability, PCRX's ROE is +0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, PCRX is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
PCRX vs VLNS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas VLNS's P/E ratio is -1.03. In terms of profitability, PCRX's ROE is +0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, PCRX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
PCRX vs DRRX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas DRRX's P/E ratio is -4.44. In terms of profitability, PCRX's ROE is +0.02%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, PCRX is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
PCRX vs TLPH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TLPH has a market cap of 55.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TLPH trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TLPH's P/E ratio is -3.96. In terms of profitability, PCRX's ROE is +0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, PCRX is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
PCRX vs INCR Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, INCR has a market cap of 53.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while INCR trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas INCR's P/E ratio is -4.76. In terms of profitability, PCRX's ROE is +0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, PCRX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
PCRX vs JUPW Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas JUPW's P/E ratio is -2.41. In terms of profitability, PCRX's ROE is +0.02%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, PCRX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
PCRX vs QLI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas QLI's P/E ratio is -4.92. In terms of profitability, PCRX's ROE is +0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, PCRX is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
PCRX vs HEXO Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas HEXO's P/E ratio is -0.26. In terms of profitability, PCRX's ROE is +0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, PCRX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
PCRX vs CPHI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CPHI has a market cap of 31.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CPHI trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CPHI's P/E ratio is -1.68. In terms of profitability, PCRX's ROE is +0.02%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, PCRX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
PCRX vs RMTI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, RMTI has a market cap of 29.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while RMTI trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas RMTI's P/E ratio is -5.40. In terms of profitability, PCRX's ROE is +0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, PCRX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RMTI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
PCRX vs CYTH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CYTH's P/E ratio is -0.80. In terms of profitability, PCRX's ROE is +0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, PCRX is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check CYTH's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
PCRX vs SHPH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SHPH has a market cap of 23.4M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SHPH trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SHPH's P/E ratio is -0.23. In terms of profitability, PCRX's ROE is +0.02%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, PCRX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SHPH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
PCRX vs TXMD Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, TXMD has a market cap of 22.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while TXMD trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas TXMD's P/E ratio is 97.30. In terms of profitability, PCRX's ROE is +0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, PCRX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
PCRX vs AYTU Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AYTU has a market cap of 21.8M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AYTU trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AYTU's P/E ratio is -1.70. In terms of profitability, PCRX's ROE is +0.02%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, PCRX is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AYTU's competition here
Optimi Health Corp. (NASDAQ: OPTH)
PCRX vs OPTH Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, OPTH has a market cap of 19.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while OPTH trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas OPTH's P/E ratio is -2.15. In terms of profitability, PCRX's ROE is +0.02%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, PCRX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
PCRX vs EVOK Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas EVOK's P/E ratio is -7.97. In terms of profitability, PCRX's ROE is +0.02%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, PCRX is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
PCRX vs ACRX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ACRX's P/E ratio is -0.31. In terms of profitability, PCRX's ROE is +0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, PCRX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ACRX's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
PCRX vs AGRX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AGRX's P/E ratio is -0.89. In terms of profitability, PCRX's ROE is +0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, PCRX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
PCRX vs CABR Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, CABR has a market cap of 9.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while CABR trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas CABR's P/E ratio is -1.36. In terms of profitability, PCRX's ROE is +0.02%, compared to CABR's ROE of -3.86%. Regarding short-term risk, PCRX is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CABR's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
PCRX vs NLTX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas NLTX's P/E ratio is -0.28. In terms of profitability, PCRX's ROE is +0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, PCRX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
PCRX vs LCI Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas LCI's P/E ratio is -0.04. In terms of profitability, PCRX's ROE is +0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, PCRX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LCI's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
PCRX vs INM Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, INM has a market cap of 7.4M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while INM trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas INM's P/E ratio is -0.44. In terms of profitability, PCRX's ROE is +0.02%, compared to INM's ROE of -1.35%. Regarding short-term risk, PCRX is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check INM's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
PCRX vs ADMP Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ADMP's P/E ratio is -0.08. In terms of profitability, PCRX's ROE is +0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, PCRX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
PCRX vs SNOA Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, SNOA has a market cap of 5.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while SNOA trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas SNOA's P/E ratio is -1.05. In terms of profitability, PCRX's ROE is +0.02%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, PCRX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
PCRX vs MNK Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas MNK's P/E ratio is -0.44. In terms of profitability, PCRX's ROE is +0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, PCRX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
PCRX vs YCBD Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, YCBD has a market cap of 4.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while YCBD trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas YCBD's P/E ratio is -0.95. In terms of profitability, PCRX's ROE is +0.02%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, PCRX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
PCRX vs FLGC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas FLGC's P/E ratio is -0.19. In terms of profitability, PCRX's ROE is +0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, PCRX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
PCRX vs GELS Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, GELS has a market cap of 4.1M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas GELS's P/E ratio is -1.02. In terms of profitability, PCRX's ROE is +0.02%, compared to GELS's ROE of -0.36%. Regarding short-term risk, PCRX is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GELS's competition here
Akanda Corp. (NASDAQ: AKAN)
PCRX vs AKAN Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, AKAN has a market cap of 2.6M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while AKAN trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas AKAN's P/E ratio is -0.02. In terms of profitability, PCRX's ROE is +0.02%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, PCRX is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
PCRX vs PLXP Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas PLXP's P/E ratio is -0.22. In terms of profitability, PCRX's ROE is +0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, PCRX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
PCRX vs ATNX Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas ATNX's P/E ratio is -0.02. In terms of profitability, PCRX's ROE is +0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, PCRX is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ATNX's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
PCRX vs UPC Comparison October 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1.5B. In comparison, UPC has a market cap of 2.2M. Regarding current trading prices, PCRX is priced at $36.38 on the NASDAQ, while UPC trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 13.99, whereas UPC's P/E ratio is -0.44. In terms of profitability, PCRX's ROE is +0.02%, compared to UPC's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check UPC's competition here